PD-1 and CTLA-4: Two checkpoints, one pathway?

被引：17
|
作者：
Walker, Lucy S. K. [1 ]
机构：
[1] UCL, Div Infect & Immun, Inst Immun & Transplantat, Royal Free Campus, London NW3 2PF, England
来源：
SCIENCE IMMUNOLOGY | 2017年 / 2卷 / 11期
基金：
英国医学研究理事会;
关键词：
T-CELLS; CD28;
D O I：
10.1126/sciimmunol.aan3864
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition
    Sun, Michel M.
    Levinson, Ralph D.
    Filipowicz, Artur
    Anesi, Stephen
    Kaplan, Henry J.
    Wang, Wei
    Goldstein, Debra A.
    Gangaputra, Sapna
    Swan, Robert T.
    Sen, H. Nida
    Gordon, Lynn K.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (02) : 217 - 227
  • [32] Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma
    Hou, Kai
    Xu, Xiaohui
    Ge, Xin
    Jiang, Jiacen
    Ouyang, Fan
    BIOFACTORS, 2024, 50 (02) : 250 - 265
  • [33] The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
    Hahn, Andrew W.
    Gill, David M.
    Pal, Sumanta K.
    Agarwal, Neeraj
    IMMUNOTHERAPY, 2017, 9 (08) : 681 - 692
  • [34] CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers
    Tuccilli, Chiara
    Baldini, Enke
    Sorrenti, Salvatore
    Catania, Antonio
    Antonelli, Alessandro
    Fallahi, Poupak
    Tartaglia, Francesco
    Barollo, Susi
    Mian, Caterina
    Palmieri, Andrea
    Carbotta, Giovanni
    Arcieri, Stefano
    Pironi, Daniele
    Vergine, Massimo
    Monti, Massimo
    Ulisse, Salvatore
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2018, 2018
  • [35] Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A
    Cho, Hyosun
    Kang, Hyojeung
    Kim, Chang Wook
    Kim, Hee Yeon
    Jang, Jeong Won
    Yoon, Seung Kew
    Lee, Chang Don
    GUT AND LIVER, 2016, 10 (02) : 288 - 294
  • [36] Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators
    Le Mercier, Isabelle
    Lines, J. Louise
    Noelle, Randolph J.
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [37] Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibition
    Heppt, M.
    Heinzerling, L.
    Kaehler, K.
    Forschner, A.
    Kirchberger, M.
    Loquai, C.
    Meissner, M.
    Meier, F.
    Terheyden, P.
    Schell, B.
    Herbst, R.
    Goeppner, D.
    Kiecker, F.
    Rafei-Shamsabadi, D.
    Haferkamp, S.
    Huber, M.
    Utikal, J.
    Ziemer, M.
    Bumeder, I
    Pfeiffer, C.
    Schd-Trcka, S.
    Schmid-Tannwald, C.
    Tietze, J.
    Eigentler, T.
    Berking, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 14 - 14
  • [38] Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    Shuang Qin
    Linping Xu
    Ming Yi
    Shengnan Yu
    Kongming Wu
    Suxia Luo
    Molecular Cancer, 18
  • [39] Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice
    Affolter, Timothy
    Llewellyn, Heather P.
    Bartlett, Derek W.
    Zong, Qing
    Xia, Shuhua
    Torti, Vince
    Ji, Changhua
    PLOS ONE, 2019, 14 (05):
  • [40] Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond
    Sharma, Padmanee
    CANCER RESEARCH, 2018, 78 (13)
12345